A complete application in a minute
Tailored resume and cover letter, ready to send.
Nurix Therapeutics seeks a Senior Clinical Trial Manager (Sr CTM) to oversee regions or multiple trials, shaping vendor strategy and budget risk management. You will mentor junior staff and serve as a primary escalation point for complex issues, ensuring alignment with Nurix’s strategic goals while representing Clinical Operations externally.
Ideal candidates have 8–10+ years in clinical operations, deep regulatory knowledge (FDA/EMA/ICH/GCP), and proven success in multi-region trials with
You’ve run trials well — now run more of them, and help others do the same. You’ll manage a portfolio of trials or a full region, own vendor strategy end-to-end, and become the person other CTMs turn to when something’s stuck.
This individual manages clinical regions and/or multiple trials simultaneously, with broad involvement in work central to Nurix’s strategic goals, and plays a key role in developing junior clinical operations staff.
Salary Range: $181,900 – $193.827 annually
The posted range applies to roles based in the San Francisco Bay Area and reflects local market conditions. Where an offer lands within that range depends on the candidate’s relevant experience, technical expertise, and how their background aligns with the role’s requirements.
Location: Onsite – Brisbane, CA
Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases. Powered by a fully AI‑integrated discovery engine capable of tackling any protein class, and coupled with unparalleled ligase expertise, Nurix’s dedicated team has built a formidable advantage in translating the science of targeted protein degradation into clinical advancements. Nurix aims to establish degrader‑based treatments at the forefront of patient care, writing medicine’s next chapter with a new script to outmatch disease.